2023 World Conference on Lung Cancer (Posters)-EP02.04. Frequency of the Number of Myeloid Derived Suppressor Cells in Patients with Lung Cancer According to Tumor Pathohistological Type

EP02.04. Frequency of the Number of Myeloid Derived Suppressor Cells in Patients with Lung Cancer According to Tumor Pathohistological Type - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses the frequency of myeloid-derived suppressor cells (MDSCs) in patients with lung cancer based on the tumor pathohistological type. Lung cancer is the leading cause of cancer death worldwide, and despite advancements in treatment, the survival rate remains poor. The tumor's immunosuppressive environment, in which MDSCs play a role, is important in tumor progression and lack of response to treatment. In particular, small cell lung cancer (SCLC) has been a focus of research. SCLC initially responds to chemotherapy but relapses in a majority of patients. The introduction of immune checkpoint inhibitors (ICIs) for extended disease SCLC has shown limited benefit. The study examined the frequency of different MDSC populations in systemic circulation and tumor microcirculation in 54 patients with locally advanced and metastatic lung cancer. The results showed that SCLC patients had the highest average values of MDSCs in both systemic and tumor circulation samples. The study suggests that further research is needed to understand the role and subtypes of MDSCs in different types of lung cancer. Overall, this research highlights the significance of MDSCs in the tumor microenvironment and their potential impact on the effectiveness of treatment in lung cancer patients.

Asset Subtitle

Jelena Vukovic

Meta Tag

Speaker Jelena Vukovic

Topic Tumor Biology: Preclinical Biology - Tumor Immunity

Keywords

myeloid-derived suppressor cells

lung cancer

tumor pathohistological type

immunosuppressive environment

small cell lung cancer

SCLC

chemotherapy

immune checkpoint inhibitors

frequency

tumor microenvironment